Shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) saw an uptick in trading volume on Monday . 159,528 shares were traded during trading, an increase of 740% from the previous session’s volume of 18,989 shares.The stock last traded at $22.86 and had previously closed at $19.50.
Analyst Upgrades and Downgrades
TLX has been the subject of several recent analyst reports. William Blair upgraded Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a report on Tuesday, November 19th. UBS Group lifted their price target on shares of Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, January 27th.
Read Our Latest Research Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Price Performance
About Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Articles
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- What Are Trending Stocks? Trending Stocks Explained
- Price Targets on NVIDIA Rise in Front of Earnings
- What Makes a Stock a Good Dividend Stock?
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
- How to Capture the Benefits of Dividend Increases
- 3 Beaten Down Healthcare Stocks Recovering in 2025
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
